Schrödinger's 12% ACV Growth Is Being Treated as a Transition Story - It May Be an AI Infrastructure Story

ACV growth is being overshadowed by transition pain

The market is valuing Schrödinger against the income-statement line that still hurts today, not the asset that may matter more tomorrow. Management has described the business as being in a planned accelerated transition to hosted software licensing, and that framing has kept attention focused on near-term revenue weakness. But if investors start viewing Schrödinger less as a transitional software vendor and more as embedded AI infrastructure in drug discovery, the relevant question changes: not whether the transition is messy, but whether demand inside real discovery workflows is holding up.

The most important number may be first-quarter ACV of $28.4 million, up 12%, with growth tied to usage scale-ups and new deployments. That matters because usage-led growth usually points to deeper product attachment, not just new-customer churn. Drug discovery revenue of $22.9 million matters for a different reason: it shows customers are still paying for discovery outcomes, not just software access.

External validation may also matter more than the market admits. Management described Lilly's announced acquisition of Ajax as confirmation of Schrödinger's track record of high-value collaborations, and it said Bunsen, an agentic AI co-scientist, designed to autonomously execute complex molecular discovery workflows is expected to launch this summer. If those workflows pull more users and more projects into the platform, the valuation narrative could shift before the income statement looks clean.

The software-revenue decline may reflect mix change more than weakening demand

Yes, software revenue was $35.6 million, a 21% decrease. That is the number bears can point to without much effort. But the same quarter also included stronger drug-discovery revenue, and management said the company is making good progress in moving customers toward hosted licensing. In other words, the revenue mix is changing faster than investor psychology is resetting.

Why the mix shift can hide stronger product engagement

Investors are still anchoring to legacy software revenue as the main health check, even as hosted licensing becomes more central. If more contracts shift into hosted form factors, the old software-revenue line can fall even while the platform becomes easier to sell, easier to access, and harder to displace.

More important, management said ACV growth was driven by usage scale-ups and new deployments, and it described customer engagement as reflecting the critical importance of our computational platform. That is a stronger signal than a simple contract count. Infrastructure tends to grow through repeated use across projects and teams, not through one-time purchases alone.

Lilly integration makes the AI-angle more concrete

The clearest proof point is not abstract AI enthusiasm. It is ecosystem integration. Schrödinger said it is collaborating with Eli Lilly to offer Lilly's AI-based platform, TuneLab, on its drug designing software, integrated into LiveDesign. That moves the story beyond tool utility and toward a more structural role inside a pharma company's own AI workflow.

Couple that with Bunsen, and the mechanism becomes easier to see. If Schrödinger's AI workflows become part of the actual decision-making process inside discovery teams, the product should become stickier and usage should deepen over time.

What the next quarter needs to prove

The next checkpoint is already close: Q2 earnings are due Aug. 6 before market open. This is not a call for perfection. It is a test of whether investors have been mistaking a reporting transition for weakening demand. The setup is already active, not theoretical: the stock has gained around 13% over the past month and remains backed by 31 hedge funds, suggesting interest without full conviction.

Three signals to watch first

• ACV is holding up while software revenue stays compressed.
  That would support the case that the software decline is a timing artifact of licensing change, not a collapse in demand.

• Drug discovery revenue keeps scaling.
  That would reinforce the idea that customers are paying for discovery outcomes, not just software licenses.

• Hosted adoption improves revenue quality.
  Management has already said the shift is underway. The next question is whether it is improving renewal durability, usage depth, and recurring-revenue stability.

When the rerating works - and when it fails

The bullish case gets stronger if the Lilly integration and Bunsen rollout make the platform look more structural rather than optional. The clearest invalidation is simpler: hosted conversion starts to obscure softer demand or weaker pricing, scale-ups cool after the current phase, or new AI features do not make workflows measurably stickier.

Watch both the numbers and the framing. SDGR looks more interesting as an AI-native discovery-platform rerating candidate than as a conventional biotech software vendor.